Cambridge Cognition Holdings (COG)

Sector:

Health Care

Index:

FTSE AIM All-Share

45.33p
   
  • Change Today:
      0.33p
  • 52 Week High: 104.00
  • 52 Week Low: 44.00
  • Currency: UK Pounds
  • Shares Issued: 35.15m
  • Volume: 23,036
  • Market Cap: £15.93m
  • RiskGrade: 282

Cambridge Cognition's sales up after investments in marketing

By Maryam Cockar

Date: Thursday 22 Sep 2016

LONDON (ShareCast) - (ShareCast News) - Cambridge Cognition' half-year revenues grew and losses were more than halved as the neuroscience software and hardware company's invested in marketing and development.
For the six months ended 30 June, revenue increased by 11.3% to £3.26, compared to the same period last year.

The AIM listed company's high-margin software and services grew 12.3% and the hardware revenue increased year-on-year due to a fulfilment of a large contract.

The underlying trend for hardware sales remained downwards, as growth in connect cloud based software reduced the company's reliance on lower margin hardware.

Revenue from the pharmaceutical clinical trial business was up 17.3% to £2.24m and revenue from the academic research business rose 4.2% to £1m, which won its largest ever order from an international biobank.

Earnings before interest, tax, depreciation and amortisation (EBITDA) losses reduced by 57% to £110,000 and loss before tax narrowed by 46% to £150,000, with loss per share reduced to 0.6p from 1.7p.

Cash balance at the end June was £1.38m, an 81.5% increase from December 2015.

In April, the company raised £1.25m from a share placing, which the company invested in sales, marketing and for technology products in the pipeline.

During the six months the company restructured and strengthened the US and Europe sales infrastructure and launched its first online testing product which led the company to secure its first pharmaceutical collaboration for the testing product.

Chief executive Steven Powell, said: "The results from the first half of the year reflect the significant advances that have been made in marketing of our core products and technology developments that have resulted in the launch of our online and wearable platforms.

"Our products and technologies are now aligned with all stages of our customers' drug development cycle and the commercial focus is now set to maximise the opportunities presented by existing sales channels."

Shares in Cambridge Cognition Holdings were down 5.88% to 72p at 0906 BST.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

COG Market Data

Currency UK Pounds
Share Price 45.33p
Change Today 0.33p
% Change 0.74 %
52 Week High 104.00
52 Week Low 44.00
Volume 23,036
Shares Issued 35.15m
Market Cap £15.93m
RiskGrade 282

COG Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
88.88% below the market average88.88% below the market average88.88% below the market average88.88% below the market average88.88% below the market average
37.5% below the sector average37.5% below the sector average37.5% below the sector average37.5% below the sector average37.5% below the sector average
Price Trend
79.04% below the market average79.04% below the market average79.04% below the market average79.04% below the market average79.04% below the market average
27.78% below the sector average27.78% below the sector average27.78% below the sector average27.78% below the sector average27.78% below the sector average
Income
1.26% below the market average1.26% below the market average1.26% below the market average1.26% below the market average1.26% below the market average
77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average
Growth
7.71% above the market average7.71% above the market average7.71% above the market average7.71% above the market average7.71% above the market average
5.56% below the sector average5.56% below the sector average5.56% below the sector average5.56% below the sector average5.56% below the sector average

What The Brokers Say

Strong Buy 0
Buy 1
Neutral 0
Sell 0
Strong Sell 0
Total 1
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

COG Dividends

No dividends found

Trades for 21-May-2024

Time Volume / Share Price
08:38 7,575 @ 44.00p
08:35 12,607 @ 44.07p
08:33 2,854 @ 44.07p

COG Key Personnel

Chair Steven John Powell
CEO Matthew Stork
CFO Stephen Symonds

Top of Page